This statistic shows the amount of registrations of newly diagnosed cases of lung cancer in England in 2021, by age group and gender. In this year, almost ************* cases were reported among men aged 70 to 74 years. It should be noted that the number of people in England in each age group varies and is therefore not necessarily a reflection of susceptibility to lung cancer.

In 2022, the mortality rate of lung cancer was the highest among those aged above 75 years of age in the European Union at ***** per 100,000 men and ***** per 100,000 women. The risk of developing lung cancer can increase by smoking, inhaling second hand smoke and exposure to asbestos.

Summary statistics of average lung cancer incidence rates and average daily smokers in percentage in 8 U.S. geographic regions, 1999–2012.

For 2023, it was estimated that there would be 25 new lung cancer cases among those between aged 15 to 29 years old. Cancer is one of the leading causes of premature death in Canada. This statistic displays the estimated number of new lung cancer cases in Canada by age group in 2023.

Mortality from lung cancer (ICD-10 C33-C34 equivalent to ICD-9 162). To reduce deaths from lung cancer. Legacy unique identifier: P00516

Lung cancer incidence rates by race, 1999–2012 (cases per 100,000).

Summary statistics of lung cancer incidence rates for Whites in 8 U.S. geographic regions, 1999–2012 (cases per 100,000).

This dataset contains Cancer Incidence data for Lung Cancer (All Stages^) including: Age-Adjusted Rate, Confidence Interval, Average Annual Count, and Trend field information for US States for the average 5 year span from 2016 to 2020.Data are segmented by sex (Both Sexes, Male, and Female) and age (All Ages, Ages Under 50, Ages 50 & Over, Ages Under 65, and Ages 65 & Over), with field names and aliases describing the sex and age group tabulated.For more information, visit statecancerprofiles.cancer.govData NotationsState Cancer Registries may provide more current or more local data.TrendRising when 95% confidence interval of average annual percent change is above 0.Stable when 95% confidence interval of average annual percent change includes 0.Falling when 95% confidence interval of average annual percent change is below 0.† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.‡ Incidence Trend data come from different sources. Due to different years of data availability, most of the trends are AAPCs based on APCs but some are APCs calculated in SEER*Stat. Please refer to the source for each area for additional information.Rates and trends are computed using different standards for malignancy. For more information see malignant.^ All Stages refers to any stage in the Surveillance, Epidemiology, and End Results (SEER) summary stage.Data Source Field Key(1) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(5) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(6) Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2022 submission).(7) Source: SEER November 2022 submission.(8) Source: Incidence data provided by the SEER Program. AAPCs are calculated by the Joinpoint Regression Program and are based on APCs. Data are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84,85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used with SEER November 2022 data.Some data are not available, see Data Not Available for combinations of geography, cancer site, age, and race/ethnicity.Data for the United States does not include data from Nevada.Data for the United States does not include Puerto Rico.

Deaths from lung cancer - Directly age-Standardised Rates (DSR) per 100,000 population Source: Office for National Statistics (ONS) Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Primary Care Trust (PCT), Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2005-07, 2007 Type of data: Administrative data

As of 2022, the age-standardized incidence rate of lung cancer among males in Polynesia was 54.7 per 100,000 population, the highest rate worldwide. The incidence rate of lung cancer among females was highest in Northern America. This statistic shows the age-standardized incidence rate of lung cancer worldwide as of 2022, by region and gender.

Data Showing - Age rates of lung cancer incidence - Plymouth - 2009 - 2013

Lung Cancer Deaths reports the number, crude rate, and age-adjusted mortality rate (AAMR) of deaths due to lung cancer.

Summary statistics for lung cancer incidence rates for Blacks and Whites in the Mid-South by gender, 1999–2012 (cases per 100,000).

Number and rate of new cancer cases diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

This dataset contains information on lung cancer risk factors across various countries, focusing on demographic details, smoking behaviors, and family history. Researchers and public health professionals can use this data to study patterns of lung cancer incidence, identify trends related to smoking and passive smoking exposure, and assess the impact of family history on lung cancer risk.

What You Can Perform with This Data:

Risk Factor Analysis: Analyze how smoking habits, exposure to secondhand smoke, and family history correlate with lung cancer risk. Comparative Study: Compare lung cancer risk factors across different countries and regions. Demographic Insights: Explore how age and gender impact the prevalence of lung cancer risk factors. Statistical Modeling: Build models to predict lung cancer risk based on various factors such as smoking history, exposure to passive smoke, and genetic predisposition. Public Health Research: Identify populations with high-risk behaviors and suggest interventions or preventive measures.

Mortality from lung cancer (ICD-10 C33-C34 equivalent to ICD-9 162). To reduce deaths from lung cancer. Legacy unique identifier: P00511

ObjectiveHungary has repeatedly been shown to have the highest cancer-related mortality and incidence in Europe. Despite lung cancer being the most abundant malignant diagnosis in Hungary, numerous concerns have been raised recently regarding the bias inherent to reported incidence estimates. Re-analysis of reimbursement claims has been suggested previously by our group as an alternative approach, offering revised figures of lung cancer incidence between 2011 and 2016. Leveraging on this methodology, we aimed at updating Hungarian lung cancer incidence estimates with an additional 5 years (2017–2021), including years affected by the COVID-19 pandemic. Additionally, we also attempted to improve the robustness of estimates by taking additional characteristics of the patient pathway into account.MethodsLung cancer patients between 2011 and 2021 were identified based on reimbursement-associated ICD-10 codes, histology codes and time patterns. Multiple query architectures were tested for sensitivity and compared to official estimates of the Hungarian National Cancer Registry (HNCR). Epidemiological trends were estimated by Poisson-regression, corrected for age and sex.ResultsA total of 89,948 lung cancer patients diagnosed in Hungary between 2011 and 2021 have been identified by our study. In 2019 alone, 7,887 patients were diagnosed according to our optimized query. ESP2013 standardized rate was estimated between 92.5/100,000 (2011) and 78.4/100,000 (2019). In 2019, standardized incidence was 106.8/100,000 for men and 59.7/100,000 for women. Up until the COVID-19 pandemic, lung cancer incidence was decreasing by 3.18% (2.1%–4.3%) yearly in men, while there was no significant decrease in women. Young age groups (40–49 and 50–59) featured the largest improvement, but women aged 60–79 are at an increasing risk for developing lung cancer. The COVID-19 pandemic resulted in a statistically significant decrease in lung cancer incidence, especially in the 50–59 age group (both sexes).ConclusionOur results show that using an optimized approach, re-analysis of reimbursement claims yields robust estimates of lung cancer incidence. According to this approach, the incidence rate of male lung cancer is declining in Hungary, in concordance with the trend observed for lung cancer mortality. Among women aged 60–79, the incidence of lung cancer has risen, requiring more attention in the near future.

Legacy unique identifier: P00509

Lung Cancer Diagnostic Tests Market Outlook

The lung cancer diagnostic tests market size was valued at USD 2.5 billion in 2023 and is projected to reach USD 6.1 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 10.5% during the forecast period. This substantial growth can be attributed to the rising prevalence of lung cancer globally, advancements in diagnostic technologies, and increasing awareness regarding early detection and treatment of lung cancer. The growing aging population and the high incidence of smoking, which is a leading cause of lung cancer, further propel the demand for diagnostic tests.

The increasing prevalence of lung cancer is one of the primary drivers of market growth. Lung cancer remains the leading cause of cancer-related deaths worldwide, necessitating the development of more accurate and early diagnostic methods. With advancements in medical technology, such as molecular diagnostics and non-invasive imaging techniques, the accuracy and efficiency of lung cancer diagnosis have significantly improved. These innovations not only enhance the detection rate but also facilitate personalized treatment plans, thereby improving patient outcomes.

Furthermore, government initiatives and funding for cancer research play a crucial role in market expansion. Many countries are investing heavily in cancer research, leading to the development of new diagnostic tools and techniques. For instance, organizations such as the National Cancer Institute (NCI) in the United States provide substantial grants for lung cancer research, fostering innovations in diagnostics. In addition, public awareness campaigns and screening programs conducted by healthcare organizations and governments encourage early diagnosis, which is vital for successful treatment and survival rates.

The integration of artificial intelligence (AI) and machine learning in diagnostic tools is another significant factor contributing to market growth. AI algorithms can analyze medical images with high precision, aiding radiologists in identifying lung cancer at earlier stages. Moreover, AI-driven software can evaluate large datasets from genetic and molecular tests, providing insights into the most effective treatment options based on individual patient profiles. This technological advancement not only enhances the accuracy of diagnostics but also reduces the time required for analysis, thereby increasing the efficiency of healthcare services.

The EGFR Mutation Test is a pivotal advancement in the realm of lung cancer diagnostics, offering a more personalized approach to treatment. This test specifically identifies mutations in the Epidermal Growth Factor Receptor (EGFR) gene, which are often present in non-small cell lung cancer (NSCLC) patients. By detecting these mutations, healthcare providers can tailor therapies that target the specific genetic alterations, thereby improving treatment efficacy and patient outcomes. The growing adoption of EGFR Mutation Tests underscores the shift towards precision medicine, where treatments are increasingly customized based on individual genetic profiles. This approach not only enhances the effectiveness of therapies but also minimizes adverse effects, as treatments are more accurately aligned with the patient's unique genetic makeup.

Regionally, North America holds the largest share of the lung cancer diagnostic tests market, followed by Europe and Asia Pacific. The dominance of North America can be attributed to the presence of advanced healthcare infrastructure, high healthcare expenditure, and a robust research landscape. The Asia Pacific region, however, is expected to witness the highest growth rate during the forecast period, driven by increasing healthcare investments, growing awareness about lung cancer, and rising incidences of the disease in countries like China and India. The growing middle-class population and improving healthcare access in these countries further support market growth.

Test Type Analysis

The lung cancer diagnostic tests market is segmented by test type into imaging tests, sputum cytology, tissue biopsy, molecular tests, and others. Imaging tests are one of the most commonly used diagnostic methods for lung cancer detection. Techniques such as X-rays, CT scans, and PET scans provide detailed visuals of the lungs, helping in identifying abnormal growths or tumors. The non-invasive nature of these tests and their ability to provide quick results make them a preferred choice among healthcare

Cancer diagnoses and age-standardised incidence rates for all types of cancer by age and sex including breast, prostate, lung and colorectal cancer.